2,253 press releases in English indexed under biotech & pharma.
Data From 13 Leading Pharmaceutical Companies Points to Execution, Governance and Partner Coordination as Key Drivers of Trial Performance Data From 13 Leading Pharmaceutical Companies Points to Execution, Governance and Partner Coordination as Key Drivers of Trial Performance
Opportunities center on real-time, high-throughput drug discovery and diagnostics, driven by SPR/BLI advances, AI analytics, CRO adoption, improved sensitivity and Asian localization. Opportunities center on real-time, high-throughput drug discovery and diagnostics, driven by SPR/BLI advances, AI analytics, CRO adoption, improved sensitivity and Asian localization.
The global point-of-care diagnostics market is projected to grow from USD 20.63 billion in 2026 to USD 31.46 billion by 2031, at an 8.8% CAGR. Growth is driven by demand for rapid, accurate and decentralized testing, alongside advances in molecular diagnostics, microfluidics, multiplex assays and portable analyzers. Biochemistry holds the largest technology share, while molecular diagnostics and infectious disease testing are set for strong growth. Clinical laboratories lead by end user, and North America dominates the market. Key players include Abbott, Roche, Danaher and Siemens Healthineers. The global point-of-care diagnostics market is projected to grow from USD 20.63 billion in 2026 to USD 31.46 billion by 2031, at an 8.8% CAGR. Growth is driven by demand for rapid, accurate and decentralized testing, alongside advances in molecular diagnostics, microfluidics, multiplex assays and portable analyzers. Biochemistry holds the largest technology share, while molecular diagnostics and infectious disease testing are set for strong growth. Clinical laboratories lead by end user, and North America dominates the market. Key players include Abbott, Roche, Danaher and Siemens Healthineers.
NGS, personalized medicine, RNA therapeutics and chronic disease testing are driving demand for automated, magnetic and microfluidic purification solutions. NGS, personalized medicine, RNA therapeutics and chronic disease testing are driving demand for automated, magnetic and microfluidic purification solutions.
SHANGHAI, Sept. 16, 2026 -- Forbes China recently released the 2026 Forbes China ESG 50 list. WuXi Biologics was named to the list for its outstanding performance in sustainable development, Green CRDMO solutions and ESG digital innovation, and was highlighted by Forbes China...
TME Pharma updates shareholders on final NOX-A12 license talks, capital discipline, minimal dilution, and capturing positive biotech market momentum.
NEW YORK, Sept. 15, 2026 -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class...
Capricor Therapeutics (CAPR) Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
NEW YORK, Sept. 15, 2026 -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. (“Beam” or the “Company”) (NASDAQ: BEAM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 15, 2026 -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK and WASHINGTON, Sept. 15, 2026 -- Royalty Pharma and Blood Cancer United today announced a $7.5 million donation from Royalty Pharma to support Blood Cancer United’s Therapy Acceleration Program (TAP), a collaborative venture philanthropy initiative designed to accelerate the development of promising blood cancer therapies through strategic equity investments and hands-on collaboration with biotech companies.
Donation marks a new phase for Blood Cancer United's venture philanthropy program, with returns reinvested to support future therapies NEW YORK, NY and WASHINGTON, Sept. 15, 2026 -- Blood Cancer United and Royalty Pharma today announced a $7.5 million donation from Royalty...